These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 36555398)

  • 1. New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment.
    Yan B; Liang Y
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy.
    Ahmadi SE; Soleymani M; Shahriyary F; Amirzargar MR; Ofoghi M; Fattahi MD; Safa M
    Cancer Gene Ther; 2023 Jul; 30(7):936-954. PubMed ID: 36854897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in delivery systems for CRISPR/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles.
    Song Z; Tao Y; Liu Y; Li J
    Front Immunol; 2024; 15():1444437. PubMed ID: 39281673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome Editing.
    Duan L; Ouyang K; Wang J; Xu L; Xu X; Wen C; Xie Y; Liang Y; Xia J
    Chembiochem; 2021 Dec; 22(24):3360-3368. PubMed ID: 34418266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9: Principle, Applications, and Delivery through Extracellular Vesicles.
    Horodecka K; Düchler M
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered Cas9 extracellular vesicles as a novel gene editing tool.
    Osteikoetxea X; Silva A; Lázaro-Ibáñez E; Salmond N; Shatnyeva O; Stein J; Schick J; Wren S; Lindgren J; Firth M; Madsen A; Mayr LM; Overman R; Davies R; Dekker N
    J Extracell Vesicles; 2022 May; 11(5):e12225. PubMed ID: 35585651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular vesicles as a potential delivery platform for CRISPR-Cas based therapy in epithelial ovarian cancer.
    Godbole N; Quinn A; Carrion F; Pelosi E; Salomon C
    Semin Cancer Biol; 2023 Nov; 96():64-81. PubMed ID: 37820858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-derived extracellular vesicles for CRISPR/Cas9 delivery: engineering strategies for cargo packaging and loading.
    Liang Y; Iqbal Z; Wang J; Xu L; Xu X; Ouyang K; Zhang H; Lu J; Duan L; Xia J
    Biomater Sci; 2022 Jul; 10(15):4095-4106. PubMed ID: 35766814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomaterial-assisted targeted and controlled delivery of CRISPR/Cas9 for precise gene editing.
    Iqbal Z; Rehman K; Xia J; Shabbir M; Zaman M; Liang Y; Duan L
    Biomater Sci; 2023 May; 11(11):3762-3783. PubMed ID: 37102700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies.
    Xu Q; Zhang Z; Zhao L; Qin Y; Cai H; Geng Z; Zhu X; Zhang W; Zhang Y; Tan J; Wang J; Zhou J
    J Control Release; 2020 Oct; 326():455-467. PubMed ID: 32711027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and prospective strategies for advancing the targeted delivery of CRISPR/Cas system via extracellular vesicles.
    Huang X; Li A; Xu P; Yu Y; Li S; Hu L; Feng S
    J Nanobiotechnology; 2023 Jun; 21(1):184. PubMed ID: 37291577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing.
    Whitley JA; Cai H
    J Extracell Vesicles; 2023 Sep; 12(9):e12343. PubMed ID: 37723839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functionalized extracellular nanovesicles as advanced CRISPR delivery systems.
    Wang S; Kong H; Zhuo C; Liu L; Lv S; Cheng D; Lao YH; Tao Y; Li M
    Biomater Sci; 2024 Jul; 12(14):3480-3499. PubMed ID: 38808607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene Editing by Extracellular Vesicles.
    Kostyushev D; Kostyusheva A; Brezgin S; Smirnov V; Volchkova E; Lukashev A; Chulanov V
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33028045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors.
    Nie D; Guo T; Yue M; Li W; Zong X; Zhu Y; Huang J; Lin M
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.